Establish the likelihood of amyloid pathology consistent with Alzheimer's disease

LifeLabs® ABeta 42/40 and p-tau217 Evaluation assesses beta-amyloid (Aβ) and phosphorylated tau (p-tau) to establish the likelihood of amyloid pathology consistent with Alzheimer's disease.

Evaluated at 91% sensitivity and 91% specificity to meet acceptable performance of blood biomarker tests[1,2]

Insights can help patients **avoid invasive and less accessible testing** such as PET scans

The **AD-Detect Likelihood Score** is a composite interpretation created through a proprietary algorithm clinically validated utilizing a real-world cohort[a,3]

[a] A well-characterized cohort from a National Institutes of Health (NIH) Alzheimer's Disease Research Center (ARDC).

The AD-Detect Likelihood Score

This panel combines Aβ42/40 and p-tau217 values into a single analytical interpretation, which has been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity corresponding to the findings of an amyloid PET scan and establishing a diagnosis of Alzheimer's disease.

These determinations are intended to be used in combination with a full clinical evaluation, inclusive of the patient's clinical history and presentation, to completely assess the presence of Alzheimer's disease.

Likelihood Score values

Low likelihood: < 0.3254

Indeterminate: 0.3254 – 0.6460

High likelihood: > 0.6460

Test name	Specimen Requirements	Turnaround time
LifeLabs® ABeta 42/40 and p-tau217 Evaluation[b]	Preferred: 2 mL (1.1 mL minimum) plasma collected in K2 EDTA lavender-top tube split into 2 equal aliquots	10 days

[b] Panel components can be ordered separately.

Visit **LifeLabs.com/alzheimers-disease** to learn more about our portfolio or **click here** to download requisition.

Stay Informed with LifeLabs

Click the 'Sign up' button below and join our email list to receive the latest news and updates on diagnostic testing for AD and other therapeutic areas.

Sign up

References

1. Weber D, Stroh M, et al. Development and clinical validation of a blood-based multibiomarker algorithm for the evaluation of brain amyloid pathology. 2025, Peer-reviewed publication pending. 2. Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology — Recommendations from the Global CEO Initiative on Alzheimer's disease. Nat Rev Neurol. 2024;20(7):426-439. doi:10.1038/s41582-024-00977-5 3. Data on file. Quest Diagnostics. AD-Detect Likelihood Score Validation, 2024.

www.LifeLabs.com